Pinealon

Overview

Pinealon is a synthetic tripeptide (Glu-Asp-Arg, sometimes labeled EDR) that originated from brain-tissue extracts. It is studied for neuroprotective and geroprotective effects, working through several proposed routes: tamping down reactive oxygen species, nudging the cell cycle, possibly slipping into DNA to influence gene expression, and easing neuroinflammation. The headline research uses are cognitive support, protection against hypoxia and oxidative stress, anti-aging benefit, and brain health in elderly populations. Like most peptides, it is sold as a research chemical that requires reconstitution and injection, so purity and storage are real concerns.

Editorial verdict

The mechanistic story is interesting, but buyers should keep expectations grounded. Nearly all the supporting data is preclinical or comes from a small number of human observational and trial reports out of a single research tradition. The animal and in vitro work is consistent, yet that is not the same as proven benefit in everyday human use. Treat the bolder marketing claims, especially anything about amino acids weaving into your DNA, with caution.

Evidence quality

We rate the research B+, weighted across 15 peer-reviewed studies (1 RCT, 3 observational, 6 animal, 4 in vitro, and 1 review). Of 15 classified findings, 13 supported the compound and 2 were mixed. The human evidence base is a single RCT, which is thin for anything claiming meaningful clinical effect.

What research shows

In cell studies, Pinealon cut ROS accumulation and necrotic cell death in a dose-dependent way, with changes in ERK 1/2 signaling and the cell cycle hinting at both antioxidant action and direct genome interaction. Other in vitro work on the EDR peptide pointed to activation of gene expression and protein synthesis relevant to neuronal function, reduced apoptosis, and possible interference with dendritic-spine loss in Alzheimer's models. A separate study found Pinealon can partially enter the DNA major groove and contact guanine atoms, with magnesium ions aiding the interaction. In animals, it raised neurogenesis and lowered neuroinflammation toward normal in old rats under hypoxia, reduced caspase-3 activity, showed the strongest antihypoxic effect among several short peptides tested, and improved learning in both young and old animals. Human observational data on locomotive workers found that two weeks of 100 mcg twice daily improved biological-age markers and adaptive responses, and combined oligopeptide regimens including Pinealon ranked among the safest interventions for biochemical and immune parameters.

Who should be cautious

There is no standardized pharmaceutical product, dosing in real-world use is poorly defined, and human safety data is minimal. Anyone outside a research context should weigh that uncertainty carefully.

Community sentiment

Across 46 community reports, sentiment ran 33% positive, 38% neutral, and 29% negative. The most cited effects were sleep and memory; the most cited downsides were insomnia and interrupted sleep, which is notable given some users take it for sleep.

Dosage

Studies typically used 100 mcg twice daily for two-week courses. Practitioners reportedly prescribe it for sleep and neuroprotection without detailed protocols. New buyers describe receiving 10 mg vials needing reconstitution, signaling research-grade sourcing rather than standardized pharmaceutical product. Some discuss intranasal delivery as potentially more effective, though protocols are not established.

Effectiveness and availability

Lab studies fairly consistently show neuroprotective, antihypoxic, and biological-age benefits, especially in elderly and stress models. Direct user feedback is sparse, often appearing only inside larger stacks alongside compounds like Semax and Selank. Pinealon is mainly sold through research-peptide vendors; general marketplace listings are widely flagged as unreliable or counterfeit, and availability is limited compared with more popular peptides.